Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Mass Ave Capital
Deal Size : $25.0 million
Deal Type : Financing
Details : The funds will enable the Company to advance its differentiated tissue-targeted Lipid Nanoparticle (ttLNP) technology to enable a new generation of highly targeted LNP-mRNA based genetic medicines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Mass Ave Capital
Deal Size : $25.0 million
Deal Type : Financing